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1. Introduction 
Calcium ions play an important role in 
fibrin monomer aggregation [1,2] and fibrin sta- 
bilization by factor XIII [3] . They also partially 
protect fibrinogen against heat denaturation [4,5] . In 
[6] we described qualitatively the protecting effect 
of Ca” in the plasmin degradation of human and 
bovine fibrinogen. We based a preparation method on 
this observation [7] in order to reduce the well known 
size heterogeneity of D-fragments. Upon exhaustive 
digestion with plasmin in the presence of Ca2+ ions 
only D-fragments with mol. wt 93 000 (D(cate)) are 
formed, and in the presence of EGTA only D-fragments 
with mol. wt 80 000 (D(EGTA)). Calcium appeared 
to protect the C-terminal part of the y-chain remnant 
in D(cate) against further plasmic attack [6,7]. 
In direct Ca”-binding studies [8] we determined 
the number and affinity of Ca”-binding sites in rat 
fibrinogen and its degradation products. 
Here we report the results obtained with human 
fibrinogen and its degradation products. Our results 
differ from those obtained in [9] but strongly sup- 
port the model suggested earlier by us for Ca2’-bind- 
ing by rat fibrinogen. 
2. Materials and methods 
Fibrin(ogen) and degradation products were 
prepared as in [7,10] . Equilibrium dialysisexperiments 
were carried out as in [8] for the rat. 
3. Results and discussion 
Figures l-3 and table 1 summarize the results of 
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Fig.1. Scatchard plot of no. Cap bound/m01 human fibrinogen 
and free [Ca*]. Details in [8]. 
the experiments. From these results it is clear that 
human fibrinogen differs from rat [8] and bovine 
[ 1 l] fibrinogen in its Ca2’-binding properties. In rat 
and bovine fibrinogen, three apparently identical 
high-affinity binding sites were deduced from the 
Fig.2. Scatchard plot of no. Ca* bound/m01 human D(cate) 
and free [Ca*] . Details in [8]. 
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Fig.3. Scatchard plot of no. Ca” bound~mol human Ddimer 
and free [Ca”] . Details in [ 81. 
Scatchard plots. From pH-Ca*+-binding studies for 
bovine fibrinogen [ 1 l] and by summation of sites in 
the degradation products of rat fibrinogen [8] it 
could be concluded that two of the three Ca*’ were 
bound at identical sites in the symmetrical fibrinogen 
molecules. 
In human fibrinogen the two identical binding sites 
(Kd 9.0 X 10m6) are discriminated from the third, 
directly in the Scatchard plot. It must be concluded 
from our data that the binding site withKd 32 X 10m6 
corresponds to one of the three apparently identical 
sites found in rat and bovine ~brinogen. Apparently 
the model suggested by us for Ca*+-bin~ng by rat 
fibrinogen is also consistent with the Ca*+-binding by 
human fibrinogen. 
Our results for human fibrinogen are at variance 
with results in [9] with human fibrinogen. They found 
three high-affinity binding sites with K, 8.7 X 10m6. 
These authors probably did not measure Ca2’-binding 
at low enough [Ca2+] to be able to discriminate 
between the K, 9 X 10e6 and Kd 32 X 10e6 sites. 
Also our results with D-dimer differ by a factor two 
from those obtained in [9] (Kd 9.5 X low6 versus 
Table 1 
Number of Ca*-binding sites and Kd values in human 
fibrinogen and fibrin(ogen) degradation products 
Class: I II 
Protein Sites Kd (W Sites Kd (M) 
Fibrinogen 2 9.0 x 1o-6 l-2 32 x lo-* 
D(Cate) 1 8.9 x 1O-6 0 - 
D-Dime1 2 4.6 X 1O-6 0 - 
our Ka 4.6 X 10m6). On the other hand our results 
for D(cate) are in fairly good agreement with the 
results obtained [9] with fragments Dr (Ka 
10.6 X 10e6 versus our result 8.9 X 10m6). Although 
no detailed information is available of the preparation 
in [9] it is likely that their Dr-fragment is identical 
with our D(cate). 
Like rat, human D-dimer binds two Ca*‘. .Their 
Kd values are lower than in the corresponding fibrin- 
ogen% This could indicate that also human fibrin (like 
in rat) Ca2* bind tighter than in ~brinogen. Human 
D(EGTA) fragments do not bind Ca*+, nor did 
E-fragments isolated from digests prepared in the 
presence of Ca2* or EGTA as in [7]. This is also in 
agreement with the corresponding rat products [8 ] . 
Furthermore, our studies on the anticlotting 
properties of D-fragments [12,13] have demonstrated 
a strong anticlotting potency of D(cate) and D-dimer 
fragments but none of D(EGTA) and E-fragments. 
In conclusion, our results show considerable dif- 
ferences with those in [9] and are consistent with our 
results obtained with the rat [8] and those obtained 
with bovine fibrinogen [ 1 l] with respect to two of 
the three high-affinity binding sites. 
These two Ca*+-binding sites protecting fibrinogen 
against further plasmic attack and the ~ticlotting 
properties of the D- and D-dimer fragments are related 
to the C-terminal parts of the y-chains. 
Direct evidence is given that the third binding site 
in human fibrinogen is different. This could only be 
deduced from circumstantial evidence in rat and 
bovine fibrinogen. Our present and previous observa- 
tions strongly suggest hat in fibrinogens in general 
three Ca*’ are bound with a hip-af~nity and that 
two of these are each bound identicaly to one of the 
two D(cate) fragments. The third site is located else- 
where in the molecules. 
It would be of interest to know the role of this 
third binding site. It might play a role in the first 
steps of fibrin polymerization. 
Further studies along these lines are in progress. 
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